In a bold move to expand its reach in specialty healthcare, Cardinal Health has announced it will acquire significant assets in gastroenterology and diabetes care through two high-stakes deals worth a combined $3.9 billion. The U.S.-based pharmaceutical and healthcare giant is set to take a controlling interest in GI Alliance, the largest independent gastroenterology care […]
Eli Lilly and Company has finalised its acquisition of Morphic Holding, Inc. in a landmark $3.2 billion deal, aimed at enhancing treatment options for inflammatory bowel disease (IBD). This acquisition underscores Lilly’s strategic expansion into the gastroenterology sector. The transaction, valued at $57 per share, is a significant premium over Morphic’s recent stock prices, reflecting […]
In a landmark deal, Takeda Pharmaceutical Company has successfully completed its previously announced acquisition of Shire, an Irish biotech leader specializing in rare diseases, for a staggering $62 billion. This acquisition marks a major step in Takeda’s ongoing transformation into a global powerhouse in biopharmaceuticals, with an expanded footprint and a deeper focus on rare […]
Dutch pharmaceutical giant Norgine has inaugurated new offices in Wettenberg, Germany, marking a significant step in its ongoing growth strategy. This move strengthens its commitment to its largest product sales market, where it has been a key player since 1928. The new facility is set to enhance the company’s operations and support services, ensuring the […]
Japanese pharmaceutical giant Takeda Pharmaceutical has announced a proposal to acquire TiGenix, a Belgium-based cell therapy company, for €520 million. This acquisition is aimed at expanding Takeda’s late-stage gastroenterology portfolio and enhancing its presence in the American specialty care market. TiGenix, established in 2000, specializes in the development of novel treatments for serious medical conditions […]